Unknown OBSERVATIONAL NCT05513664

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

To Evaluate Real-World Effectiveness of Osimertinib for Patients With Advanced or Metastatic Epidermal Growth Factor Receptor 20exon Insertion Mutation (20ins) Non-Small Cell Lung Cancer (NSCLC)

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions EGFR Exon20 Insertion Mutations Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions Osimertinib

Updated 4 times since 2022 Last updated: Aug 23, 2022 Started: Sep 30, 2022 Primary completion: Jun 30, 2023 Completion: Aug 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates EGFR Exon20 Insertion Mutations and Locally Advanced or Metastatic Non-Small Cell Lung Cancer and is currently ongoing. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Aug 2024 — Sep 2024 [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Shanghai JMT-Bio Inc.

Data source: Shanghai JMT-Bio Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoding, China , Beijing, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hefei, China , Jinan, China , Nanjing, China , Shanghai, China , Shanxi, China and 6 more locations